Tenax Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $49.3K | $158.9K | $1.2M | $363.8K | $103.2K |
| Cost of Revenue | — | — | $0 | $0 | $129.8K | $43.1K | $51.3K | $219.2K |
| Gross Profit | — | — | $0 | $0 | $-104.1K | $49.6K | $49.3K | $103.2K |
| Gross Margin | — | — | — | 0.0% | -65.5% | 4.2% | 13.5% | 100.0% |
| Operating Expenses | ||||||||
| Research & Development | $32.7M | $12.7M | $13.1M | $6.7M | $3.0M | $2.5M | $2.5M | $2.7M |
| SG&A Expense | $23.7M | $6.8M | $6.2M | $7.2M | $13.8M | $3.7M | $6.1M | $7.7M |
| Operating Income | $-56.4M | $-19.5M | $-52.7M | $-14.8M | $-16.6M | $-5.2M | $-8.2M | $10.6M |
| Operating Margin | — | — | — | -30,062.8% | -10,452.1% | -435.7% | -2,259.7% | 10,238.4% |
| Interest Expense | $0 | $23.0K | $0 | $49.1K | $2.2M | $4.2M | $7.4M | $-171.6K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $-8.0M | $0 | $0 | — | — | — |
| Net Income | $-52.6M | $-17.6M | $-43.9M | $-14.1M | $-19.5M | $-9.4M | $-15.7M | $10.4M |
| Net Margin | — | — | — | -28,571.6% | -12,296.2% | -790.6% | -4,319.2% | 10,127.6% |
| EPS (Basic) | $-1.34 | $-0.38 | $-0.17 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $-1.34 | $-0.38 | $-0.17 | $0.00 | $0.00 | $0.00 | $-0.01 | $0.00 |
| Shares Outstanding (Basic) | 39.2M | 45.8M | 257.3M | 5.14B | 5.14B | 4.53B | 3.56B | 64.09B |
| Shares Outstanding (Diluted) | 39.2M | 45.8M | 257.3M | 5.14B | 5.14B | 4.83B | 3.81B | 64.09B |
| Dividends Per Share | — | — | — | — | — | — | — | — |